SHP-1 agonists
By developing SHP-1 agonist compounds and activating SHP-1, the treatment challenges of autoimmune diseases and cancer have been solved, achieving regulation of immune responses and cancer cells, and significantly improving patients' health.
CN122295337APending Publication Date: 2026-06-26DANA FARBER CANCER INSTITUTE INC +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- DANA FARBER CANCER INSTITUTE INC
- Filing Date
- 2024-11-19
- Publication Date
- 2026-06-26
AI Technical Summary
Technical Problem
Current technologies lack effective SHP-1 agonists for the treatment of autoimmune diseases and certain cancers, and the negative regulatory role of SHP-1 in cell signaling has not been fully utilized.
Method used
A series of SHP-1 agonist compounds were developed, with specific structures consisting of R1, R2, and R4, where R1 is a halogroup, amino group, or C1–C4 alkoxy group, R2 is -X-NHR3, R3 is -C(O)R4, R4 is a C2–C4 alkyl group or C2–C4 alkenyl group, and X is a phenyl or pyridinyl substituent, administered in pharmaceutically acceptable salt form.
Benefits of technology
Activating SHP-1 regulates immune responses, alleviates symptoms of autoimmune diseases, inhibits cancer cell proliferation and invasion, and improves patient survival outcomes.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122295337A_ABST
Abstract
This invention provides an SHP-1 agonist of Formula I.
Need to check novelty before this filing date? Find Prior Art